Launched on June 23, 2005, the Invesco Biotechnology & Genome ETF (PBE) is a passively managed exchange traded fund designed ...

Discover the best biotech ETFs to diversify your portfolio, gain exposure to cutting-edge biotech innovations, and reduce risk in a volatile sector.

Insider buying matters in every industry, but it carries a special weight in biotechnology. In most businesses, management has a reasonably clear view of sales trends, margins, customer demand, and ...

It's normal for biotechs to buy intellectual property. It can be risky for a company to underinvest in its own R&D capabilities. 10 stocks we like better than Summit Therapeutics › For most of the ...

FBT selects 30 biotechnology stocks based on sales, sales as a percentage of R&D expenditures, and R&D growth compared to three years ago. The ETF launched 19 years ago and has delivered exceptional ...

SANA develops engineered cell therapies for diabetes, autoimmune diseases, and cancer using ex vivo HIP and in vivo fusogen platforms. SC291 is their CD19‑targeted allogeneic CAR-T candidate which ...

IBB has delivered stronger returns than IYH but with dramatically sharper swings in both directions. Here is how to decide which trade-off fits your portfolio.

Biotech stocks have a way of making smart people do dumb things. It starts innocently enough. You read about a "breakthrough" that sounds like it came straight out of science fiction. A tiny company ...

The biotech world is a prime target for risk-tolerant investors seeking out companies with the potential for dramatic gains. Firms in this space often either make it big—spiking upon news of a ...

Lixte Biotechnology (ISIN: US53833K1060) develops novel cancer therapies targeting key tumor regulators. North American investors eye its clinical-stage assets amid biotech volatility. Understand the ...